Medical Xpress November 15, 2024
Stephanie Dutchen, Harvard Medical School

Harvard Medical School researchers have taken another decisive step in their efforts to develop a gene therapy for people with Usher syndrome type 1F, a rare condition that causes deafness and progressive blindness.

A new way of delivering a corrected version of the faulty gene that causes Usher syndrome—PCDH15—restored hearing in mouse models and showed potential in retinal organoids and for improving , the team reports in the Journal of Clinical Investigation.

This is the second experimental for Usher syndrome developed by the lab of David Corey, the Bertarelli Professor of Translational Medical Science in the Blavatnik Institute at HMS. Earlier research showed that a different gene-delivery strategy restored hearing in mice. The new method provides...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
At JPM, Eli Lilly’s CEO Explains Why Mounjaro, Zepbound Sales Were Lower Than Expected
NIH's unfinished business
Lilly blames slower-than-expected growth for 2024 sales miss
AbbVie to write off $3.5B over failed schizophrenia drug

Share This Article